PD-L1 competitively inhibits the binding of Cetuximab to EGFR,leading to the resistance of Cetuximab to BRAF mutant colorectal cancer
作者单位：The first affiliated hospital of China medical university
会议名称：《2019年中国肿瘤标志物学术大会暨第十三届肿瘤标志物青年科学家论坛》
会议日期：2019年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：Objective Cetuximab is monoclonal antibody directed against EGFR that inhibit its downstream signaling *** the key target drug in the treatment of colorectal cancer,it has been studied that Cetuximab provides a clear clinical benefit in the treatment in patients with RAS wild-type metastatic colorectal ***,